VERTEX Company Profile
✉ Email this page to a colleague
What is the competitive landscape for VERTEX, and what generic alternatives to VERTEX drugs are available?
VERTEX has eight approved drugs.
There are fifty-one US patents protecting VERTEX drugs.
There are seven hundred and ninety patent family members on VERTEX drugs in fifty-four countries and eighty-five supplementary protection certificates in nineteen countries.
Summary for VERTEX
| International Patents: | 790 |
| US Patents: | 51 |
| Tradenames: | 5 |
| Ingredients: | 5 |
| NDAs: | 8 |
| PTAB Cases with VERTEX as patent owner: | See PTAB cases with VERTEX as patent owner |
Drugs and US Patents for VERTEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharms Inc | TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | GRANULES;ORAL | 217660-001 | Apr 26, 2023 | RX | Yes | No | 10,646,481 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Vertex Pharms Inc | TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | TABLET;ORAL | 212273-001 | Oct 21, 2019 | RX | Yes | Yes | 9,670,163 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Vertex Pharms Inc | ORKAMBI | ivacaftor; lumacaftor | GRANULE;ORAL | 211358-001 | Aug 7, 2018 | RX | Yes | No | 9,931,334 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VERTEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Vertex Pharms | INCIVEK | telaprevir | TABLET;ORAL | 201917-001 | May 23, 2011 | 8,529,882 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Premature patent expirations for VERTEX
Expiration due to failure to pay maintenance fee
| Patent Number | Expiration Date |
|---|---|
| ⤷ Subscribe | ⤷ Subscribe |
International Patents for VERTEX Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 101068547 | ⤷ Subscribe |
| South Korea | 20130042034 | ⤷ Subscribe |
| European Patent Office | 1716122 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for VERTEX Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3170818 | 2020/035 | Ireland | ⤷ Subscribe | PRODUCT NAME: A COMBINATION OF (A) 3-(6-(1-(2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5- YL)CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID (LUMACAFTOR) AND (B) N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3- CARBOXAMIDE (IVACAFTOR) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/15/1059 20151124 |
| 1320540 | 2012/009 | Ireland | ⤷ Subscribe | PRODUCT NAME: TELAPREVIR, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT AND/OR SOLVATE THEREOF OR SOLVATES OF SUCH SALTS; REGISTRATION NO/DATE: EU/1/11/720/001 20110919 |
| 2404919 | 132016000049236 | Italy | ⤷ Subscribe | PRODUCT NAME: LUMACAFTOR O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE, O UN SUO ESTERE PROFARMACO(ORKAMBI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/1059/001, 20151124 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
